Aripiprazole is a novel antipsychotic medication that is used to treat a number of psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder. Clinical trials have established its efficacy and favorable tolerability profile. Nevertheless, infrequent undesirable adverse events are often encountered during wide-scale everyday clinical use. There are a few mania/hypomania cases associated with second-generation antipsychotic treatment. Induction of mania, described for almost all secondgeneration antipsychotic, may be one of the rare adverse events of aripiprazole therapy. In this study, a female patient with chronic schizophrenia who had never presented history of mood episodes, in which manic symptoms de...
International audienceImportance: Some reports have raised concerns regarding a potential psychiatri...
Background: Aripiprazole differs from other atypical antipsychotics in its pharmacological and clini...
David J MuzinaCenter for Mood Disorders Treatment and Research, Cleveland Clinic Neurological Instit...
Aripiprazole, a new antipsychotic drug is commenly used in treatment of schizophrenia and bipolar di...
Aripiprazole is a novel antipsychotic with a unique pharmacological profile as a dopamine partial ag...
Bipolar disorder (BD) is a chronic illness that is characterized by recurrent episodes of mania, dep...
Aripiprazole is a 2<sup>nd</sup> generation antipsychotic medication, atypical neuroleptic used for ...
Bipolar disorder (BD) is a chronic illness that is characterized by recurrent episodes of mania, dep...
Schizophrenia is generally a chronic and disabling mental illness. Pharmacological therapy, which is...
Schizophrenia is generally a chronic and disabling mental illness. Pharmacological therapy, which is...
Schizophrenia is generally a chronic and disabling mental illness. Pharmacological therapy, which is...
Aripiprazol é um antipsicótico atípico (AAt) frequentemente indicado para o tratamento agudo da mani...
Background: Aripiprazole is the first dopamine D2 receptor partial-agonist approved for treatment of...
Schizophrenia is a chronic disabling disease which in the majority of cases requires long-term treat...
A number of double-blind, randomized, controlled trials have confirmed the clinical efficacy of arip...
International audienceImportance: Some reports have raised concerns regarding a potential psychiatri...
Background: Aripiprazole differs from other atypical antipsychotics in its pharmacological and clini...
David J MuzinaCenter for Mood Disorders Treatment and Research, Cleveland Clinic Neurological Instit...
Aripiprazole, a new antipsychotic drug is commenly used in treatment of schizophrenia and bipolar di...
Aripiprazole is a novel antipsychotic with a unique pharmacological profile as a dopamine partial ag...
Bipolar disorder (BD) is a chronic illness that is characterized by recurrent episodes of mania, dep...
Aripiprazole is a 2<sup>nd</sup> generation antipsychotic medication, atypical neuroleptic used for ...
Bipolar disorder (BD) is a chronic illness that is characterized by recurrent episodes of mania, dep...
Schizophrenia is generally a chronic and disabling mental illness. Pharmacological therapy, which is...
Schizophrenia is generally a chronic and disabling mental illness. Pharmacological therapy, which is...
Schizophrenia is generally a chronic and disabling mental illness. Pharmacological therapy, which is...
Aripiprazol é um antipsicótico atípico (AAt) frequentemente indicado para o tratamento agudo da mani...
Background: Aripiprazole is the first dopamine D2 receptor partial-agonist approved for treatment of...
Schizophrenia is a chronic disabling disease which in the majority of cases requires long-term treat...
A number of double-blind, randomized, controlled trials have confirmed the clinical efficacy of arip...
International audienceImportance: Some reports have raised concerns regarding a potential psychiatri...
Background: Aripiprazole differs from other atypical antipsychotics in its pharmacological and clini...
David J MuzinaCenter for Mood Disorders Treatment and Research, Cleveland Clinic Neurological Instit...